Galmed Pharmaceuticals Ltd. (GLMD) is up over 46% at $5.67 in pre-market trading Tuesday, on news of the company regaining compliance with the minimum bid price requirement outlined in the Nasdaq Listing Rule. The company was previously notified by Nasdaq on September 19, 2023, that its ordinary shares had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Allarity Therapeutics Inc. (ALLR) announced that two patients enrolled in a phase II clinical trial of its investigational drug Stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy. This remarkably lengthy treatment period highlights the potential of Stenoparib to provide durable clinical benefit, even in heavily pre-treated ovarian cancer patients who have limited treatment options, noted the company. Shares are up over 30% at $4.40.
For comments and feedback: editorial@rttnews.com